Terrapinn Release: Experts From Merck & Co., GlaxoSmithKline, Pfizer, Sanofi Pasteur And More To Debate Breakthroughs For Vaccines For Ebola, Zika And Cancer.

WASHINGTON, March 7, 2016 /PRNewswire/ -- On March 29-31, over 600 vaccine specialists will converge in Washington D.C. for the 16th World Vaccine Congress. This annual industry gathering has asserted its position as a critical meeting platform delivering in-depth insights on the state of the industry and solutions to the latest challenges faced by professionals.

The recent rampant cases of Ebola and Zika have served to highlight the urgency under which vaccine professionals work. But developing, testing and delivering vaccines in record time to avoid potential pandemics is just one side of the coin. Recent breakthroughs in vaccines for cancer, influenza and clinical development demonstrate the break-neck pace of this fast-evolving, multi-faceted industry. But most importantly, it underlines the pressing need for professionals to share knowledge in a time-efficient way and be inspired by their peers so as to keep a fresh perspective on their work and permanently challenge the status quo.

The complex array of vaccine topics, sectors and specializations will be once more deciphered at the 16th World Vaccine Congress with the help of over 150 renowned industry experts fromGSK, Pfizer, Sanofi Pasteur, Merck, Inovio, Advaxis and more. For the second year, this high-profile event will boast 7 co-located conferences on a wide range of topics, including cancer and immunotherapy, veterinary vaccines, clinical trials and development, bioprocessing and manufacturing as well as emerging and re-emerging diseases such as Zika and Ebola.

This variety of options will give participants the 'a la carte' experience they deserve, as they will be able to build their own bespoke program based on the topics most relevant to their activities.

About the unrivalled scientific content of the congress, Dr. Gregory A. Poland, Director of Mayo Vaccine Research Group at Mayo Clinic recently stated that "I come there because I want to learn from other people. The conferences are a who's who in the fields of vaccinology. I've met industry partners, I've made new collaborations there and there are stacks of different conferences or specialty tracks that occur simultaneously. () There are really top people in the vaccine field and we spend 2.5 days together, engaging, learning from one another, teaching one another. Where else are you going to get something like that?"

Dr. Gregory A. Poland has taken an active part in the development of the congress' ground-breaking program by heading the Scientific Committee alongside other high-profile experts, including Dr. Cyril Gay, Senior National Program Leader, Office of National Programs at USDA, Dr. Michael Watson, VP Vaccination Policy & Advocacy at Sanofi Pasteur, Dr. Bruce Gellin, Deputy Assistant Secretary for Health & Director at NVPO, Dr. George Siber, CSO of ClearPath Vaccines, Dr. Leonard Friedland, VP Scientific Affairs & Public Health Vaccines in North America at GSK and Dr. Luis Jodar, VP Global Vaccines at Pfizer. 

In addition, 13 of the 150 high-profile speakers have recently taken part in an exclusive interview compiling their thoughts and insights on the vaccine industry. Among key contributors are Dr. Joseph Voyce, Director of Vaccine Process Development at Merck, Dr. Jerome Kim, Director General at the International Vaccine Institute, Dr. Peter Hotez, President of the Sabin Vaccine Institute, Dr. Jerald Saldoff, Senior Advisor CEO at Janssen Infectious Diseases and Vaccines, Dr. Stanley Plotkin, Emeritus Professor At the University of Pennsylvania School of Medicine and Dr. Jim Tartaglia, VP New Vaccine Project Head of North America for Sanofi Pasteur.

As explained by Wing-Yun Cheung, Program Director of the 16th World Vaccine Congress "By compiling the opinion of so many professionals, this interview is a highly interesting summary of the current state of the industry. Not only does it give a perspective on a variety of vaccine fields such as cancer, emerging diseases or veterinary vaccines, most importantly it depicts the hurdles that need to be overcome for professionals to continue making new breakthroughs. It is a great reflection of the multidisciplinary approach the congress offers and will give the opportunity to hundreds of professionals to gain valuable takeaways that can be directly reapplied in their own field of vaccine challenges."

The 16th World Vaccine Congress will take place on March 29-31 in Washington D.C. The 9th VIE Awards will take place alongside the congress to reward professionals and organizations for their outstanding contributions to the vaccine industry. For more information about the congress and awards ceremony, please visit www.terrapinn.com/VaccineUSA2016 

To download the interview compiling the thoughts of top vaccine experts, please visit www.terrapinn.com/VaccineUSAInterview

The World Vaccine Congress Washington is well-established as the leading annual event on vaccines. Now turning 16, participants are guaranteed the best experience on-site ever as it will bring together 150+ expert speakers, 600+ participants taking part in 7 co-located conferences on the following topics: cancer & immunotherapy; influenza & respiratory, emerging & re-emerging diseases; clinical development & trials, bioprocessing & manufacturing; veterinary vaccines; vaccine partnerships.

As always, the Congress will cover the crucial topics which are affecting the whole sector. From responding to new outbreaks threatening the world to exploring the technological developments which are changing how vaccines are researched, manufactured and distributed.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/experts-from-merck-gsk-pfizer-sanofi-pasteur-and-more-to-debate-breakthroughs-for-vaccines-for-ebola-zika-and-cancer-300231037.html

SOURCE Terrapinn Inc.

Back to news